With regards to SM, KRAS and/or NRAS mutations have been sporadically reported in ISM [12,97] and MCL cases [10,29], while they are more frequently found among SM-AHN patients, particularly in cases associated with poor-prognosis myeloid neoplasms (i.e., AML) [10,29,46,50,51,68,84] (Table 3 and Table S3); in this setting, some authors have suggested that these mutations might have an adverse prognostic impact [120]. Here, NRAS is linked to myeloid neoplasm.